Journal of Peking University (Health Sciences) ›› 2026, Vol. 58 ›› Issue (4): 833-841. doi: 10.19723/j.issn.1671-167X.2026.04.021

Previous Articles     Next Articles

Long-term evolution, effect analysis and future trend of the burden of gastritis and duodenitis in China: An analysis based on GBD 2023

Qinghua WANG, Tiantian SHEN, Xiaowei LU, Congcong LIAO, Shiwei XU, Yan LI*()   

  1. Department of Geriatrics, Shanghai East Hospital, Tongji University, Shanghai 200120, China
  • Received:2025-11-26 Online:2026-08-18 Published:2026-06-30
  • Contact: Yan LI

RICH HTML

  

Abstract:

Objective: To explore the evolutionary trends of the disease burden of gastritis and duodenitis (GD) in China from 1990 to 2023, to clarify the driving factors of changes in this burden, to predict the disease burden situation from 2024 to 2040, and to provide data support for formulating GD prevention and control strategies. Methods: Based on the Global Burden of Disease Study (GBD) 2023 data, the Joinpoint regression model was applied to analyze the annual average percentage change (AAPC) of age-standardized incidence rate, age-standardized prevalence rate, age-standardized mortality rate, and age-standardized disability-adjusted life years (DALY) rate of GD in China from 1990 to 2023. The age-period-cohort model was used to investigate the effects of age, period, and cohort on incidence, prevalence, and mortality risks. Three factors—population structure change, epidemiological change, and population growth—were identified to determine their driving effects on the disease burden. The auto-regressive integrated moving average (ARIMA) time series model was employed to forecast the future disease burden. Results: From 1990 to 2023, the number of GD incident cases in China increased from 6.158 8 million to 9.354 5 million, the number of prevalent cases rose from 8.770 6 million to 13.145 9 million, the number of deaths decreased from 19 800 to 17 200, and the number of DALY slightly declined from 902 400 person-years to 851 600 person-years. The AAPCs of age-standardized incidence rate, age-standardized prevalence rate, age-standardized mortality rate, and age-standardized DALY rate were -1.08%, -1.18%, -3.81%, and -2.89%, respectively (all P < 0.001). Joinpoint regression analysis showed that all age-standardized rates presented a phased downward trend. Age-period-cohort model analysis revealed that the incidence and prevalence risks peaked in the 55-59 years age group, while the mortality risk increased significantly with age. The period effect of incidence and prevalence risks first increased and then decreased, whereas the period effect of mortality risk showed a conti-nuous downward trend; the cohort risk exhibited a decreasing trend across all the groups. Decomposition analysis indicated that population growth and structural change promoted the increase in incident and prevalent cases (the overall contribution rates to the incident cases were 165.66% and 167.00%, respectively), while epidemiological change was the main factor driving their decrease (with an overall contribution rate of -232.66% to the incident cases). Additionally, epidemiological change was the core factor for the reduction in deaths (with an overall contribution rate of 490.07%). The ARIMA time series model predicted that by 2040, the number of incident cases would rise to 11.086 1 million, the number of prevalent cases to 15.279 6 million, the mortality rate to 0.48 per 100 000 population, and the DALY rate to 26.18 per 100 000 population. Conclusion: From 1990 to 2023, the age-standardized disease burden of GD in China was significantly alleviated, with population factors and epidemiological changes jointly driving the burden changes. Although the number of incident and prevalent cases will increase in the future, the mortality and disability burden will continue to decrease. It is necessary to formulate targeted prevention and control strategies based on age, cohort characteristics, and driving factors.

Key words: Gastritis, Duodenitis, Global burden of disease, China

CLC Number: 

  • R573

Table 1

Comparison of GD burden in China between 1990 and 2023"

Indicator 1990 2023
Total Male Female Total Male Female
Incidence
    Incident cases/(×104) 615.88(480.19-794.52) 292.77(228.67-377.46) 323.11(252.22-415.37) 935.45(729.09-1 182.95) 407.40(319.33-507.83) 528.04(410.28-675.16)
    Incidence rate/(per 105) 838.88(654.06-1 082.20) 777.12(606.96-1 001.89) 903.98(705.67-1 162.10) 851.98(664.03-1 077.39) 733.95(575.29-914.87) 972.65(755.74-1 243.63)
    Age-standardized incidence rate/(per 105) 700.22(551.64-874.14) 650.80(513.11-810.21) 750.13(592.28-940.96) 489.05(391.66-599.60) 437.47(349.09-529.29) 541.46(430.51-669.24)
Prevalence
    Prevalent cases/(×104) 877.06(674.68-1 108.67) 414.01(321.48-525.19) 463.05(355.15-584.33) 1 314.59(1 034.83-1 636.95) 559.05(445.26-687.11) 755.54(595.71-945.24)
    Prevalence rate/(per 105) 1 194.62(918.97-1 510.08) 1 098.90(853.32-1 394.02) 1 295.51(993.63-1 634.80) 1 197.28(942.49-1 490.87) 1 007.14(802.15-1 237.84) 1 391.69(1 097.30-1 741.12)
    Age-standardized prevalence rate/(per 105) 1 004.91(793.38-1 230.01) 929.54(738.53-1 142.69) 1 080.74(843.31-1 317.66) 678.98(544.78-821.73) 597.67(488.01-720.55) 761.24(606.68-923.71)
Death
    Number of deaths/(×104) 1.98(1.17-3.28) 1.05(0.44-2.05) 0.92(0.43-1.59) 1.72(1.03-2.31) 0.94(0.46-1.40) 0.78(0.48-1.06)
    Mortality rate/(per 105) 2.70(1.59-4.47) 2.80(1.17-5.45) 2.59(1.21-4.46) 1.57(0.94-2.11) 1.70(0.84-2.52) 1.45(0.89-1.97)
    Age-standardized mortality rate/(per 105) 3.02(1.78-5.02) 3.27(1.38-6.12) 2.73(1.28-4.74) 0.81(0.49-1.08) 0.96(0.48-1.38) 0.67(0.42-0.92)
DALY
    DALY/(×104 person-years) 90.24(61.53-134.31) 47.11(28.11-77.23) 43.13(26.52-62.51) 85.16(63.32-114.63) 41.49(28.44-54.89) 43.66(31.83-60.17)
    DALY rate/(per 105) 122.92(83.82-182.95) 125.05(74.62-205.01) 120.69(74.21-174.89) 77.56(57.67-104.41) 74.75(51.25-98.89) 80.44(58.65-110.83)
    Age-standardized DALY rate/(per 105) 118.19(81.26-173.20) 122.01(74.15-195.68) 113.87(71.70-163.06) 43.51(31.87-58.47) 43.58(29.97-57.48) 43.55(31.14-60.58)

Figure 1

Changes in the burden of GD by sex in China, 1990-2023 GD, gastritis and duodenitis; DALY, disability-adjusted life year."

Table 2

Joinpoint analysis of age-standardized rates of GD in China, 1990-2023"

Items Trend stage Total Male Female
Year APC/% Year APC/% Year APC/%
Age-standardized incidence rate 1 1990-1995 -0.94*(-1.13 to -0.77) 1990-2005 -0.61*(-0.63 to -0.59) 1990-1994 -1.49*(-1.61 to -1.39)
2 1995-2005 -0.21*(-0.28 to -0.14) 2005-2010 -4.42*(-4.55 to -4.29) 1994-2003 0.04*(0.01 to 0.09)
3 2005-2010 -4.02*(-4.25 to -3.80) 2010-2015 -0.46*(-0.60 to -0.34) 2003-2006 -0.44*(-0.78 to -0.11)
4 2010-2023 -0.64*(-0.68 to -0.61) 2015-2020 -1.02*(-1.15 to -0.90) 2006-2009 -4.92*(-5.24 to -4.60)
5 2020-2023 -0.05 (-0.27 to 0.15) 2009-2012 -1.22*(-1.56 to -0.90)
6 2012-2015 -0.29 (-0.62 to 0.04)
7 2015-2023 -0.74*(-0.78 to -0.71)
Age-standardized prevalence rate 1 1990-1994 -1.29*(-1.49 to -1.11) 1990-2000 -0.82*(-0.89 to -0.77) 1990-1994 -1.56*(-1.76 to -1.37)
2 1994-2000 -0.49*(-0.63 to -0.36) 2000-2005 -0.01 (-0.24 to 0.23) 1994-2000 -0.28*(-0.43 to -0.15)
3 2000-2005 0.20*(0.02 to 0.40) 2005-2010 -5.18*(-5.40 to -4.97) 2000-2005 0.43*(0.24 to 0.64)
4 2005-2010 -4.54*(-4.73 to -4.37) 2010-2023 -0.70*(-0.74 to -0.67) 2005-2010 -3.98*(-4.17 to -3.79)
5 2010-2023 -0.69*(-0.72 to -0.66) 2010-2023 -0.69*(-0.73 to -0.66)
Age-standardized mortality rate 1 1990-1998 -4.29*(-4.52 to -4.08) 1990-1998 -4.00*(-4.63 to -3.38) 1990-1998 -4.19*(-5.18 to -3.20)
2 1998-2004 0.30 (-0.05 to 0.66) 1998-2004 0.26 (-0.70 to 1.25) 1998-2005 -0.72 (-1.86 to 0.42)
3 2004-2008 -7.44*(-7.97 to -6.92) 2004-2013 -5.81*(-6.16 to -5.48) 2005-2008 -10.34*(-14.72 to -5.74)
4 2008-2013 -5.75*(-6.06 to -5.44) 2013-2021 -1.81*(-2.26 to -1.37) 2008-2013 -5.82*(-7.12 to -4.51)
5 2013-2017 -1.03*(-1.66 to -0.41) 2021-2023 -9.09*(-12.64 to -5.40) 2013-2017 -0.44 (-2.74 to 1.90)
6 2017-2021 -3.34*(-4.02 to -2.66) 2017-2023 -5.04*(-5.87 to -4.21)
7 2021-2023 -7.97*(-9.35 to -6.57)
Age-standardized DALY rate 1 1990-1998 -3.13*(-3.44 to -2.84) 1990-1998 -3.40*(-3.64 to -3.16) 1990-1998 -2.94*(-3.14 to -2.74)
2 1998-2005 -0.86*(-1.27 to -0.46) 1998-2004 -0.44*(-0.85 to -0.03) 1998-2005 -0.84*(-1.08 to -0.60)
3 2005-2009 -6.68*(-7.61 to -5.75) 2004-2012 -5.42*(-5.61 to -5.25) 2005-2009 -6.80*(-7.41 to -6.20)
4 2009-2012 -4.24*(-6.15 to -2.30) 2012-2021 -1.96*(-2.13 to -1.80) 2009-2012 -4.01*(-5.36 to -2.65)
5 2012-2023 -2.22*(-2.38 to -2.07) 2021-2023 -4.35*(-5.88 to -2.80) 2012-2023 -2.18*(-2.29 to -2.08)

Figure 2

Age-period-cohort model of GD incidence, prevalence, and mortality risks in China, 1990-2023 GD, gastritis and duodenitis; RR, relative risk."

Figure 3

Decomposition analysis of changes in GD burden in China, 1990-2023"

Figure 4

Projection of the burden of GD in China, 2024—2040 ARIMA, autoregressive integrated moving average; DALY, disability-adjusted life year; GD, gastritis and duodenitis."

1
Wang L , Jiang W , Li H . Global, regional, and national burden of gastritis and duodenitis from 1990 to 2021 with projections to 2050:A systematic analysis of the Global Burden of Disease Study 2021[J]. Int J Med Sci, 2025, 22 (11): 2570- 2582.

doi: 10.7150/ijms.109762
2
Zhao L , Zhang F , Kuang D , et al. Mediating effect of gastrointestinal symptoms on dietary behavior and quality of life in Chinese adults with chronic gastritis: A cross-sectional study[J]. Front Med (Lausanne), 2023, 10, 1178897.
3
Zhang Z , Chen S , Li S , et al. Association of Helicobacter pylori related chronic atrophic gastritis and gastric cancer risk: A literature review[J]. Front Med (Lausanne), 2025, 12, 1504749.
4
Lahner E , Conti L , Annibale B , et al. Current perspectives in atrophic gastritis[J]. Curr Gastroenterol Rep, 2020, 22 (8): 38.

doi: 10.1007/s11894-020-00775-1
5
Li J , Pan J , Xiao D , et al. Chronic atrophic gastritis and risk of incident upper gastrointestinal cancers: A systematic review and meta-analysis[J]. J Transl Med, 2024, 22 (1): 429.

doi: 10.1186/s12967-023-04736-w
6
秦建茹, 王峰. 慢性胃炎患者焦虑抑郁状况调查及危险因素[J]. 中国卫生工程学, 2022, 21 (6): 965- 967.
7
Zhang Z , Zhang X . Chronic atrophic gastritis in different ages in South China: A 10-year retrospective analysis[J]. BMC Gastro-enterol, 2023, 23 (1): 37.

doi: 10.1186/s12876-023-02662-1
8
王暖凤, 初海坤, 黄树民, 等. 慢性萎缩性胃炎患者临床流行病学分析[J]. 中国公共卫生, 2017, 33 (7): 1109- 1111.
9
赵丁慧. 延安市某三甲医院儿童胃镜检查结果特征分析[D]. 延安: 延安大学, 2024.
10
GBD results[EB/OL]. (2025-10-12)[2025-10-25]. https://vizhub.healthdata.org/gbd-results.
11
朱风尚, 朱国英, 陈利, 等. 建党100年来我国消化病学发展回顾之管见[J/OL]. 中华消化病与影像杂志(电子版), 2021, 11(4): 145-148. https://rs.yiigle.com/cmaid/1561940.
12
姜元喜, 陈莹, 许树长. 中国消化内镜质量控制现状、思考及未来[J]. 同济大学学报(医学版), 2020, 41 (6): 805- 810.
13
王昊成, 张振玉. 二联疗法根除幽门螺杆菌的昨天、今天和明天[J]. 胃肠病学和肝病学杂志, 2025, 34 (8): 1106- 1112.
14
Greuter T , Manser C , Pittet V , et al. Gender differences in inflammatory bowel disease[J]. Digestion, 2020, 101 (Suppl 1): 98- 104.
15
Lahner E , Dilaghi E , Cingolani S , et al. Gender-sex differences in autoimmune atrophic gastritis[J]. Transl Res, 2022, 248, 1- 10.
16
许诗涵, 周显祝, 杜奕奇, 等. 中国胃癌早筛早诊早治高质量发展的思考[J]. 中国实用内科杂志, 2025, 45 (5): 365- 372.
17
Zhu Z , Wang Q , Sun Q , et al. Improving access to medicines and beyond: The national volume-based procurement policy in China[J]. BMJ Glob Health, 2023, 8 (7): e011535.

doi: 10.1136/bmjgh-2022-011535
18
Idris M , Smiley A , Patel S , et al. Risk factors for mortality in emergently admitted patients with acute gastric ulcer: An analysis of 15, 538 patients in national inpatient sample, 2005-2014[J]. Int J Environ Res Public Health, 2022, 19 (23): 16263.

doi: 10.3390/ijerph192316263
19
Lin S , Gao T , Sun C , et al. Association of dietary patterns and endoscopic gastric mucosal atrophy in an adult Chinese population[J]. Sci Rep, 2019, 9 (1): 16567.

doi: 10.1038/s41598-019-52951-7
20
Piscione M , Mazzone M , Di Marcantonio MC , et al. Eradication of helicobacter pylori and gastric cancer: A controversial relationship[J]. Front Microbiol, 2021, 12, 630852.

doi: 10.3389/fmicb.2021.630852
21
Marshall B . Epidemiology of Helicobacter in Chinese families: A foundation for cost-effective eradication strategies?[J]. Gut, 2024, 73 (5): 870- 871.

doi: 10.1136/gutjnl-2023-329786
22
吴志国, 王先升, 杜敏, 等. 体检人群胃癌风险筛查结果分析及对策研究[J]. 智慧健康, 2024, 10 (9): 21- 24.
23
阳国兴, 杜光会, 张冲, 等. 健康教育在慢性胃炎护理干预中效果的随机对照试验[J]. 中国循证医学杂志, 2018, 18 (8): 812- 815.
24
Lupu A , Miron IC , Cernomaz AT , et al. Epidemiological characteristics of helicobacter pylori infection in children in northeast Romania[J]. Diagnostics (Basel), 2023, 13 (3): 408.

doi: 10.3390/diagnostics13030408
[1] Qingbo WANG,Hongqiao FU. Main characteristics and historical evolution of China' s health financing transition [J]. Journal of Peking University (Health Sciences), 2024, 56(3): 462-470.
[2] Ting JING,Hua JIANG,Ting LI,Qianqian SHEN,Lan YE,Yindan ZENG,Wenxin LIANG,Gang FENG,Man-Yau Szeto Ignatius,Yumei ZHANG. Relationship between serum 25-hydroxyvitamin D and handgrip strength in middle-aged and elderly people in five cities of Western China [J]. Journal of Peking University (Health Sciences), 2024, 56(3): 448-455.
[3] Jia-hui DENG,Xiao-lin HUANG,Xiao-xing LIU,Jie SUN,Lin LU. The past, present and future of sleep medicine in China [J]. Journal of Peking University (Health Sciences), 2023, 55(3): 567-封三.
[4] Rui-jie CAO,Zhong-qiang YAO,Peng-qing JIAO,Li-gang CUI. Comparison of diagnostic efficacy of different classification criteria for Takayasu arteritis in Chinese patients [J]. Journal of Peking University (Health Sciences), 2022, 54(6): 1128-1133.
[5] Li ZHANG,Ji-fang GONG,Hong-ming PAN,Yu-xian BAI,Tian-shu LIU,Ying CHENG,Ya-chi CHEN,Jia-ying HUANG,Ting-ting XU,Fei-jiao GE,Wan-ling HSU,Jane SHI,Xi-chun HU,Lin SHEN. Atezolizumab therapy in Chinese patients with locally advanced or metastatic solid tumors: An open-label, phase Ⅰ study [J]. Journal of Peking University (Health Sciences), 2022, 54(5): 971-980.
[6] Xiao-xuan LIU,Xiao-hui DUAN,Shuo ZHANG,A-ping SUN,Ying-shuang ZHANG,Dong-sheng FAN. Genetic distribution in Chinese patients with hereditary peripheral neuropathy [J]. Journal of Peking University (Health Sciences), 2022, 54(5): 874-883.
[7] Zhe LIANG,Fang-fang FAN,Yan ZHANG,Xian-hui QIN,Jian-ping LI,Yong HUO. Rate and characteristics of H-type hypertension in Chinese hypertensive population and comparison with American population [J]. Journal of Peking University (Health Sciences), 2022, 54(5): 1028-1037.
[8] XU Ying, Ci-ren-yang-jin. Analysis of the relationship between high altitude polycythemia and peptic ulcer bleeding [J]. Journal of Peking University (Health Sciences), 2022, 54(1): 161-165.
[9] WANG Zhi-cheng,GUO Yan. Association between community socioeconomic status and adults’ self-rated health in China [J]. Journal of Peking University (Health Sciences), 2021, 53(2): 314-319.
[10] XU Xiao-feng, CHEN Qian, ZHAO Yi-pu, HU Xiu-ying. Investigation and analysis of the activities of daily living of the aged at home in wes-tern China [J]. Journal of Peking University(Health Sciences), 2018, 50(3): 457-462.
[11] SI Ya-qin, TANG Xun, ZHANG Du-dan, HE Liu, CAO Yang, WANG Jin-wei, LI Na, LIU Jian-jiang, GAO Pei, HU Yong-hua. Effectiveness of different screening strategies for primary prevention of cardiovascular diseases in a rural northern Chinese population [J]. Journal of Peking University(Health Sciences), 2018, 50(3): 443-449.
[12] YANG Yu, ZHAO Hou-yu, ZHAN Si-yan. Necessity and feasibility of data sharing of cohort studies#br# #br# [J]. Journal of Peking University(Health Sciences), 2018, 50(2): 381-385.
[13] DONG Yan-hui, WANG Zheng-he, YANG Zhao-geng, WANG Xi-jie, CHEN Yan-jun, ZOU Zhi-yong, MA Jun. Epidemic status and secular trends of malnutrition among children and adolescents aged 7-18 years from 2005 to 2014 in China [J]. Journal of Peking University(Health Sciences), 2017, 49(3): 424-432.
[14] CHEN Xiao-kun, LIN Wei-cheng, ZHANG Peng, KUANG Si-jie, HUANG Wei, WANG Tian-bing. Trauma first aid system:development and present situation [J]. Journal of Peking University(Health Sciences), 2017, 49(2): 368-封三.
[15] LIU Guo-feng, SUN Mei-ping, WANG Zhi-yong, JIAN Wei-yan. Association analysis between urbanization and non-communicable diseases and health-related behavior [J]. Journal of Peking University(Health Sciences), 2016, 48(3): 478-482.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!